Iterum Therapeutics shares are trading higher after the company announced the Phase 3 REASSURE trial met the primary endpoint of non-inferiority to Augmentin.

ITERUM THERAPEUTICS PLC -2.76%

ITERUM THERAPEUTICS PLC

ITRM

1.41

-2.76%

Iterum Therapeutics shares are trading higher after the company announced the Phase 3 REASSURE trial met the primary endpoint of non-inferiority to Augmentin.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via